Literature DB >> 34172895

Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.

Jean Pegliasco1,2,3, Pierre Hirsch4, Christophe Marzac1,2,5, Françoise Isnard6, Jean-Côme Meniane7, Caroline Deswarte4, Philippe Pellet8, Céline Lemaitre8, Gwendoline Leroy8, Graciela Rabadan Moraes1,9, Hélène Guermouche4, Barbara Schmaltz-Panneau1,2, Florence Pasquier2,3, Chrystelle Colas8,10, Patrick R Benusiglio8, Odile Bera11, Jean-Henri Bourhis3, Eolia Brissot6, Olivier Caron12, Samy Chraibi3, Pascale Cony-Makhoul13, Christine Delaunay-Darivon14, Simona Lapusan6, Flore Sicre de Fontbrune15, Pascal Fuseau11, Albert Najman6, William Vainchenker1,2,16, François Delhommeau4, Jean-Baptiste Micol1,2,3, Isabelle Plo1,2, Christine Bellanné-Chantelot17,18.   

Abstract

The germline predisposition associated with the autosomal dominant inheritance of the 14q32 duplication implicating ATG2B/GSKIP genes is characterized by a wide clinical spectrum of myeloid neoplasms. We analyzed 12 asymptomatic carriers and 52 patients aged 18-74 years from six families, by targeted sequencing of 41 genes commonly mutated in myeloid malignancies. We found that 75% of healthy carriers displayed early clonal hematopoiesis mainly driven by TET2 mutations. Molecular landscapes of patients revealed two distinct routes of clonal expansion and leukemogenesis. The first route is characterized by the clonal dominance of myeloproliferative neoplasms (MPN)-driver events associated with TET2 mutations in half of cases and mutations affecting splicing and/or the RAS pathway in one-third of cases, leading to the early development of MPN, mostly essential thrombocythemia, with a high risk of transformation (50% after 10 years). The second route is distinguished by the absence of MPN-driver mutations and leads to AML without prior MPN. These patients mostly harbored a genomic landscape specific to acute myeloid leukemia secondary to myelodysplastic syndrome. An unexpected result was the total absence of DNMT3A mutations in this cohort. Our results suggest that the germline duplication constitutively mimics hematopoiesis aging by favoring TET2 clonal hematopoiesis.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34172895     DOI: 10.1038/s41375-021-01319-w

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  54 in total

1.  Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.

Authors:  Daria V Babushok; Monica Bessler; Timothy S Olson
Journal:  Leuk Lymphoma       Date:  2015-12-23

2.  Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.

Authors:  Amit Sud; Subhayan Chattopadhyay; Hauke Thomsen; Kristina Sundquist; Jan Sundquist; Richard S Houlston; Kari Hemminki
Journal:  Blood       Date:  2018-07-10       Impact factor: 22.113

Review 3.  Genetic predisposition to MDS: clinical features and clonal evolution.

Authors:  Alyssa L Kennedy; Akiko Shimamura
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

4.  A landscape of germ line mutations in a cohort of inherited bone marrow failure patients.

Authors:  Olivier Bluteau; Marie Sebert; Thierry Leblanc; Régis Peffault de Latour; Samuel Quentin; Elodie Lainey; Lucie Hernandez; Jean-Hugues Dalle; Flore Sicre de Fontbrune; Etienne Lengline; Raphael Itzykson; Emmanuelle Clappier; Nicolas Boissel; Nadia Vasquez; Mélanie Da Costa; Julien Masliah-Planchon; Wendy Cuccuini; Anna Raimbault; Louis De Jaegere; Lionel Adès; Pierre Fenaux; Sébastien Maury; Claudine Schmitt; Marc Muller; Carine Domenech; Nicolas Blin; Bénédicte Bruno; Isabelle Pellier; Mathilde Hunault; Stéphane Blanche; Arnaud Petit; Guy Leverger; Gérard Michel; Yves Bertrand; André Baruchel; Gérard Socié; Jean Soulier
Journal:  Blood       Date:  2017-11-16       Impact factor: 22.113

5.  Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation.

Authors:  Elisa Rumi; Francesco Passamonti; Matteo G Della Porta; Chiara Elena; Luca Arcaini; Laura Vanelli; Cecilia Del Curto; Daniela Pietra; Emanuela Boveri; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Journal:  J Clin Oncol       Date:  2007-11-12       Impact factor: 44.544

6.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

7.  Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.

Authors:  Christine Bellanné-Chantelot; Isabelle Chaumarel; Myriam Labopin; Florence Bellanger; Véronique Barbu; Claudia De Toma; François Delhommeau; Nicole Casadevall; William Vainchenker; Gilles Thomas; Albert Najman
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

Review 8.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

9.  Disease evolution and outcomes in familial AML with germline CEBPA mutations.

Authors:  Kiran Tawana; Jun Wang; Aline Renneville; Csaba Bödör; Robert Hills; Chey Loveday; Aleksandar Savic; Frederik W Van Delft; Jennifer Treleaven; Panayiotis Georgiades; Elizabeth Uglow; Norio Asou; Naokuni Uike; Maruša Debeljak; Janez Jazbec; Philip Ancliff; Rosemary Gale; Xavier Thomas; Valerie Mialou; Konstanze Döhner; Lars Bullinger; Beatrice Mueller; Thomas Pabst; Matthias Stelljes; Brigitte Schlegelberger; Eva Wozniak; Sameena Iqbal; Jessica Okosun; Shamzah Araf; Anne-Katrine Frank; Felicia B Lauridsen; Bo Porse; Claus Nerlov; Carolyn Owen; Inderjeet Dokal; John Gribben; Matthew Smith; Claude Preudhomme; Claude Chelala; Jamie Cavenagh; Jude Fitzgibbon
Journal:  Blood       Date:  2015-07-10       Impact factor: 22.113

10.  The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.

Authors:  Ana Rio-Machin; Tom Vulliamy; Nele Hug; Amanda Walne; Kiran Tawana; Shirleny Cardoso; Alicia Ellison; Nikolas Pontikos; Jun Wang; Hemanth Tummala; Ahad Fahad H Al Seraihi; Jenna Alnajar; Findlay Bewicke-Copley; Hannah Armes; Michael Barnett; Adrian Bloor; Csaba Bödör; David Bowen; Pierre Fenaux; Andrew Green; Andrew Hallahan; Henrik Hjorth-Hansen; Upal Hossain; Sally Killick; Sarah Lawson; Mark Layton; Alison M Male; Judith Marsh; Priyanka Mehta; Rogier Mous; Josep F Nomdedéu; Carolyn Owen; Jiri Pavlu; Elspeth M Payne; Rachel E Protheroe; Claude Preudhomme; Nuria Pujol-Moix; Aline Renneville; Nigel Russell; Anand Saggar; Gabriela Sciuccati; David Taussig; Cynthia L Toze; Anne Uyttebroeck; Peter Vandenberghe; Brigitte Schlegelberger; Tim Ripperger; Doris Steinemann; John Wu; Joanne Mason; Paula Page; Susanna Akiki; Kim Reay; Jamie D Cavenagh; Vincent Plagnol; Javier F Caceres; Jude Fitzgibbon; Inderjeet Dokal
Journal:  Nat Commun       Date:  2020-02-25       Impact factor: 14.919

View more
  3 in total

1.  Standardization of Cell Culture Conditions and Routine Genomic Screening under a Quality Management System Leads to Reduced Genomic Instability in hPSCs.

Authors:  Francisco J Molina-Ruiz; Clelia Introna; Georgina Bombau; Mireia Galofre; Josep M Canals
Journal:  Cells       Date:  2022-06-21       Impact factor: 7.666

Review 2.  The dual role of autophagy in acute myeloid leukemia.

Authors:  Wonhyoung Seo; Prashanta Silwal; Ik-Chan Song; Eun-Kyeong Jo
Journal:  J Hematol Oncol       Date:  2022-05-07       Impact factor: 23.168

3.  The prognostic value of autophagy related genes with potential protective function in Ewing sarcoma.

Authors:  Jian Wen; Lijia Wan; Xieping Dong
Journal:  BMC Bioinformatics       Date:  2022-07-28       Impact factor: 3.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.